Published Research

An Inside Look at Employee Health Trends

An Inside Look at Employee Health Trends

PHM is pleased to be a contributing partner to Springbuk’s 2023 Employee Health Trends report. The newly released report provides recommendations that will impact how benefits leaders plan, deliver, and evaluate employee benefits programs.

  1. Effects of COVID-19 on costs and health
  2. Surges in cancer costs
  3. Specialty drug use
  4. Telemedicine & mental health services

Dr. Natalya Gertsik, PHM’s Vice President, ClearCancer Solution Management, offers key insights on earlier cancer detection, improving outcomes, and reducing cancer-related spending.

Read More

Ask Our Experts

FDA Approves New Alzheimer’s Treatment: What to know About Leqembi® (lecanemab)

FDA Approves New Alzheimer’s Treatment: What to know About Leqembi® (lecanemab)

Leqembi® (lecanemab) was approved to treat Alzheimer’s disease in January, 2023 under the FDA’s Accelerated Approval process for diseases with an unmet need for treatment.1 The manufacturers, Eisai pharmaceuticals, plan to submit data for full FDA approval by the end of March 2023.

Here, we answer some common questions about Leqembi and summarize what is known about its safety and effectiveness. Patients and their families should speak with their physician and weigh the potential benefits and risks before deciding whether to seek treatment with Leqembi.
Read More

Subscribe to our Newsletter


A doctor takes a patient's blood pressure.

Contact

Want to speak with a
representative?

Connect

Follow us
on LinkedIn